仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab （HY-P9913）. Urelumab can be used for the research of diffuse large B-cell lymphoma （DLBCL）, follicular lymphoma （FL）, and other types of non-Hodgkin lymphoma （NHL）